Apalutamide (Erleada™) 60 mg or 240 mg tablets

DRUG3 trials

Sponsors

ORIC Pharmaceuticals, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Conditions

Castrate Sensitive Prostate CancerMetastatic CancerMetastatic Hormone-sensitive Prostate CancerMetastatic Prostate CancerProstate Cancer

Phase 1

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

RecruitingNCT05413421

ORIC PharmaceuticalsMetastatic Prostate Cancer

Start: 2022-06-01End: 2026-09-30Target: 250Updated: 2025-08-11

Phase 3

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

Not yet recruitingNCT07333066

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARDMetastatic Hormone-sensitive Prostate Cancer

Start: 2026-03-31End: 2030-03-31Target: 320Updated: 2026-01-12

Unknown Phase

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

RecruitingNCT06652607

Fondazione Policlinico Universitario Agostino Gemelli IRCCSCastrate Sensitive Prostate Cancer, Metastatic Cancer, Prostate Cancer

Start: 2024-12-20End: 2028-04-30Target: 152Updated: 2025-03-12

Related Papers

Abstract 7120: Rinzimetostat, an allosteric EED inhibitor with best-in-class properties for the treatment of prostate cancer, is effective in PRC2 methyltransferase-resistant settings in preclinical studies

Cancer Research2026-04-03

Abstract 7132: Rinzimetostat blockade of PRC2 activity, a key mechanism of treatment resistance, improves response of androgen receptor pathway inhibition across a spectrum of prostate cancer models

Cancer Research2026-04-03

Abstract A048: PRC2 inhibition enhances KRAS inhibitor response to delay treatment relapse in KRAS-mutant preclinical lung and colorectal cancer models

Molecular Cancer Therapeutics2025-10-22

Abstract C032: PRC2 inhibition enhances AR inhibitor response to delay treatment relapse in castration-sensitive prostate cancer by restricting adaptation of tumor cells in preclinical studies

Molecular Cancer Therapeutics2025-10-22

Abstract 452: ORIC-944, a PRC2 inhibitor with best-in-class properties, restores luminal features and restricts adaptation in prostate cancer models, conferring synergy with AR pathway inhibitors

Cancer Research2025-04-21

Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer

Cancer Research2024-04-052 citations

Abstract 6586: ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models

Cancer Research2024-03-224 citations

Abstract 2791: Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer

Cancer Research2023-04-04